Lucid Diagnostics Q2 2026 Earnings Report

Lucid Diagnostics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.04
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Lucid Diagnostics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.43 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lucid Diagnostics Announcement Details

• Quarter: Q2 2026
• Date: 8/12/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 12, 2026
• Conference Call Time: 8:30AM ET

Lucid Diagnostics (NASDAQ:LUCD) is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States. The company’s test is billed under existing procedural codes, and Lucid engages with payers to secure coverage and reimbursement. In addition to its core oral cancer test, the company is developing complementary assays and workflow enhancements aimed at broadening its diagnostic portfolio and supporting earlier intervention in head and neck malignancies.

Headquartered in the Pacific Northwest, Lucid Diagnostics began trading on the NASDAQ under the ticker LUCD in mid-2021 following a strategic reorganization and capital raise. The senior management team comprises professionals with backgrounds in in-vitro diagnostics, clinical laboratory operations and life-science commercialization. Looking ahead, Lucid is focused on expanding its sales footprint, advancing payer relationships and exploring international distribution agreements to extend access to its non-invasive oral cancer detection platform.